Merdad V. Parsey's Insider Trades & SAST Disclosures
Merdad V. Parsey's most recent trade in Ardelyx Inc was a trade of 64,457 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on April 28, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Merdad V. Parsey.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
Showing you 100 results sorted by most recent dates.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Ardelyx Inc | Merdad V. Parsey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2025 | 64,457 | 64,457 | - | - | Stock Option (Right to Buy) | |
| Ardelyx Inc | Merdad V. Parsey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2025 | 42,056 | 42,056 (0%) | 0% | 0 | Common Stock | |
| ArriVent BioPharma Inc. | Merdad V. Parsey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Apr 2025 | 28,346 | 28,346 | - | - | Stock Option (right to buy) | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Dec 2024 | 3,820 | 36,753 | - | - | Restricted Stock Unit | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Dec 2024 | 3,820 | 84,621 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Dec 2024 | 1,771 | 82,850 (0%) | 0% | 92.3 | 163,534 | Common Stock | |
| Gilead Sciences, Inc. | Parsey Merdad V. | Chief Medical Officer | 27 Nov 2024 | 88,119 | 99,599 (0%) | 0% | 92 | 8,106,948 | Common Stock | |
| Gilead Sciences, Inc. | Parsey V. Merdad | Chief Medical Officer | 27 Nov 2024 | 88,119 | 196 | - | - | Non-qualified Stock Option (Right to Buy) | ||
| Gilead Sciences, Inc. | V. Merdad Parsey | Chief Medical Officer | 27 Nov 2024 | 88,119 | 245,012 (0%) | 0% | 65.4 | 5,761,220 | Common Stock | |
| Gilead Sciences, Inc. | V. Merdad Parsey | Chief Medical Officer | 27 Nov 2024 | 57,294 | 187,718 (0%) | 0% | 91.8 | 5,259,297 | Common Stock | |
| Gilead Sciences, Inc. | V. Merdad Parsey | Chief Medical Officer | 27 Nov 2024 | 57,294 | 64,376 | - | - | Non-qualified Stock Option (Right to Buy) | ||
| Gilead Sciences, Inc. | Merdad Parsey V. | Chief Medical Officer | 27 Nov 2024 | 57,294 | 156,893 (0%) | 0% | 57.9 | 3,318,468 | Common Stock | |
| Gilead Sciences, Inc. | Parsey V. Merdad | Chief Medical Officer | 27 Nov 2024 | 10,399 | 80,801 (0%) | 0% | 92 | 956,708 | Common Stock | |
| Gilead Sciences, Inc. | Parsey V. Merdad | Chief Medical Officer | 27 Nov 2024 | 5,200 | 94,399 (0%) | 0% | 91.8 | 477,381 | Common Stock | |
| Gilead Sciences, Inc. | Merdad Parsey V. | Chief Medical Officer | 27 Nov 2024 | 3,199 | 91,200 (0%) | 0% | 91.8 | 293,679 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 06 Nov 2024 | 25,000 | 125,189 (0%) | 0% | 57.9 | 1,448,000 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 06 Nov 2024 | 25,000 | 121,670 | - | - | Non-qualified Stock Option (Right to Buy) | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 06 Nov 2024 | 20,590 | 104,599 (0%) | 0% | 91.5 | 1,883,985 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 06 Nov 2024 | 5,000 | 99,599 (0%) | 0% | 91.5 | 457,500 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 01 Oct 2024 | 2,000 | 100,189 (0%) | 0% | 83.8 | 167,660 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 12 Sep 2024 | 25,000 | 146,670 | - | - | Non-qualified Stock Option (Right to Buy) | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 12 Sep 2024 | 25,000 | 123,435 (0%) | 0% | 57.9 | 1,448,000 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 12 Sep 2024 | 21,246 | 102,189 (0%) | 0% | 84.5 | 1,795,287 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Sep 2024 | 3,821 | 40,573 | - | - | Restricted Stock Unit | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Sep 2024 | 3,821 | 100,201 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Sep 2024 | 1,766 | 98,435 (0%) | 0% | 81.4 | 143,823 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 01 Jul 2024 | 2,000 | 96,380 (0%) | 0% | 68.6 | 137,260 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Jun 2024 | 3,820 | 44,394 | - | - | Restricted Stock Unit | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Jun 2024 | 3,820 | 100,124 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Jun 2024 | 1,744 | 98,380 (0%) | 0% | 65.3 | 113,796 | Common Stock | |
| Sagimet Biosciences Inc - ... | Merdad V. Parsey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Jun 2024 | 51,459 | 51,459 | - | - | Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 01 Apr 2024 | 2,000 | 96,304 (0%) | 0% | 73.0 | 145,920 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2024 | 89,660 | 89,660 | - | - | Non-qualified Stock Option (Right to Buy) | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2024 | 17,640 | 48,214 | - | - | Restricted Stock Unit | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2024 | 6,946 | 103,107 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2024 | 6,946 | 30,574 | - | - | Restricted Stock Unit | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2024 | 4,803 | 98,304 (0%) | 0% | 75.1 | 360,801 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2024 | 3,455 | 37,520 | - | - | Restricted Stock Unit | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2024 | 3,455 | 96,161 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences, Inc. | Parsey V. Merdad | Chief Medical Officer | 28 Feb 2024 | 8,230 | 92,706 (0%) | 0% | 72.7 | 598,624 | Common Stock | |
| Gilead Sciences, Inc. | Parsey Merdad V. | Chief Medical Officer | 28 Feb 2024 | 2,000 | 100,936 (0%) | 0% | 73.2 | 146,360 | Common Stock | |
| Gilead Sciences, Inc. | Parsey Merdad V. | Chief Medical Officer | 31 Jan 2024 | 56,624 | 126,325 (0%) | 0% | 0 | Common Stock | ||
| Gilead Sciences, Inc. | V. Parsey Merdad | Chief Medical Officer | 31 Jan 2024 | 23,709 | 102,616 (0%) | 0% | 78.3 | 1,855,466 | Common Stock | |
| Gilead Sciences, Inc. | V. Parsey Merdad | Chief Medical Officer | 31 Jan 2024 | 20,229 | 69,701 (0%) | 0% | 0 | Common Stock | ||
| Gilead Sciences, Inc. | Parsey V. Merdad | Chief Medical Officer | 10 Dec 2023 | 2,779 | 40,975 | - | - | Restricted Stock Unit | ||
| Gilead Sciences, Inc. | V. Parsey Merdad | Chief Medical Officer | 10 Dec 2023 | 2,779 | 72,909 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences, Inc. | Merdad Parsey V. | Chief Medical Officer | 10 Dec 2023 | 1,269 | 71,640 (0%) | 0% | 79.0 | 100,276 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 12 Sep 2023 | 1,501 | 70,130 (0%) | 0% | 77.0 | 115,562 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Sep 2023 | 2,779 | 43,754 | - | - | Restricted Stock Unit | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Sep 2023 | 2,779 | 72,909 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Sep 2023 | 1,278 | 71,631 (0%) | 0% | 76 | 97,128 | Common Stock | |
| Sagimet Biosciences Inc - ... | Merdad V. Parsey | Director | 18 Jul 2023 | 327,309 | 0 | - | - | Series E Preferred Stock | ||
| Sagimet Biosciences Inc - ... | Merdad V. Parsey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 23,839 | 0 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | Merdad V. Parsey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 23,839 | 23,839 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | Merdad V. Parsey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 23,216 | 0 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | Merdad V. Parsey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 23,216 | 23,216 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | Merdad V. Parsey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 8,677 | 8,677 | - | - | Series A Common Stock | |
| Sagimet Biosciences Inc - ... | Merdad V. Parsey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 8,677 | 0 | - | - | Common Stock | |
| Sagimet Biosciences Inc - ... | Merdad V. Parsey | Director | 18 Jul 2023 | 4,117 | 12,794 | - | - | Series A Common Stock | ||
| Sagimet Biosciences Inc - ... | Merdad V. Parsey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 3,349 | 0 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | Merdad V. Parsey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 3,349 | 3,349 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | Merdad V. Parsey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 2,086 | 2,086 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | Merdad V. Parsey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 2,086 | 0 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | Merdad V. Parsey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 18 Jul 2023 | 144 | 0 | - | - | Stock Option (Right to Buy) | |
| Sagimet Biosciences Inc - ... | Merdad V. Parsey | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 18 Jul 2023 | 144 | 144 | - | - | Stock Option (Right to Buy) | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 13 Jun 2023 | 1,485 | 29,402 (0%) | 0% | 76.9 | 114,197 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Jun 2023 | 2,779 | 46,533 | - | - | Restricted Stock Unit | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Jun 2023 | 2,779 | 32,181 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Jun 2023 | 1,294 | 30,887 (0%) | 0% | 78.1 | 101,087 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 13 Mar 2023 | 6,126 | 70,130 (0%) | 0% | 79.0 | 483,893 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2023 | 76,000 | 76,000 | - | - | Non-qualified Stock Option (Right to Buy) | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2023 | 16,665 | 49,312 | - | - | Restricted Stock Unit | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2023 | 7,999 | 81,584 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2023 | 7,999 | 32,647 | - | - | Restricted Stock Unit | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2023 | 5,328 | 76,256 (0%) | 0% | 79.5 | 423,576 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2023 | 3,455 | 40,646 | - | - | Restricted Stock Unit | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2023 | 3,455 | 73,585 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 01 Mar 2023 | 12,984 | 70,130 (0%) | 0% | 80.0 | 1,038,225 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 15 Feb 2023 | 376 | 83,114 (0%) | 0% | 56.4 | 21,199 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 24 Jan 2023 | 43,715 | 100,487 (0%) | 0% | 0 | Common Stock | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 24 Jan 2023 | 29,644 | 56,772 (0%) | 0% | 0 | Common Stock | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 24 Jan 2023 | 17,749 | 82,738 (0%) | 0% | 84.0 | 1,491,271 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 30 Dec 2022 | 553 | 45,556 (0%) | 0% | 85.3 | 47,187 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Dec 2022 | 1,039 | 46,595 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Dec 2022 | 1,039 | 44,101 | - | - | Restricted Stock Unit | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Dec 2022 | 486 | 46,109 (0%) | 0% | 88.0 | 42,753 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Nov 2022 | 5,099 | 45,140 | - | - | Restricted Stock Unit | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Nov 2022 | 5,099 | 47,824 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Nov 2022 | 2,268 | 45,556 (0%) | 0% | 82.6 | 187,337 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Sep 2022 | 1,039 | 43,206 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Sep 2022 | 1,039 | 50,239 | - | - | Restricted Stock Unit | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Sep 2022 | 481 | 42,725 (0%) | 0% | 65.3 | 31,400 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Jun 2022 | 1,039 | 42,652 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Jun 2022 | 1,039 | 51,278 | - | - | Restricted Stock Unit | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Jun 2022 | 485 | 42,167 (0%) | 0% | 60.7 | 29,459 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2022 | 171,670 | 171,670 | - | - | Non-qualified Stock Option (Right to Buy) | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2022 | 27,840 | 52,317 | - | - | Restricted Stock Unit | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2022 | 4,157 | 24,477 | - | - | Restricted Stock Unit | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2022 | 4,157 | 44,770 (0%) | 0% | - | Common Stock | ||
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2022 | 3,505 | 41,265 (0%) | 0% | 57.9 | 203,010 | Common Stock | |
| Gilead Sciences, Inc. | Merdad V. Parsey | Chief Medical Officer | 10 Mar 2022 | 3,455 | 40,613 (0%) | 0% | - | Common Stock |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges